Clene Inc.

CLNN

NASDAQ. Currency in USD

1.04 -0.04 ( -3.70% )

Real time prices: December 19

Market Cap.
76.77M
Beta (5Y monthly)
0.17
Price/Earnings
-
EPS (TTM)
-0.76
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
329,999
1y Target Est.
9.17
Day's Range
0.97
-
1.17
52 Week's Range
0.87
-
5.13

Historical Summary

Performance
EPS growth
Share Buybacks

About Clene Inc.

Sector
Healthcare
Industry
Biotechnology
Website
https://clene.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
62.20M
Employees
95
Address
6550 South Millrock Drive, Salt Lake City, UT, United States, 84121
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Latest news

Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3
Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3

Conference Call and Webcast Set for 8:30 a.m. EDT Conference Call and Webcast Set for...
By GlobeNewswire Inc. - 17 weeks ago

Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference
Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference

SALT LAKE CITY, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with...
By GlobeNewswire Inc. - 18 weeks ago

Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates
Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates

Clene Inc. (CLNN) delivered earnings and revenue surprises of -4.76% and 46.15%, respectively, for the...
By Zacks Investment Research - 24 weeks ago

Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis
Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis

SALT LAKE CITY, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with...
By GlobeNewswire Inc. - 24 weeks ago

Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights
Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights

SALT LAKE CITY, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with...
By GlobeNewswire Inc. - 24 weeks ago

Why Is Turquoise Hill Resources Down By 18%: Here Are 31 Stocks Moving Premarket
Why Is Turquoise Hill Resources Down By 18%: Here Are 31 Stocks Moving Premarket

Gainers Plus Therapeutics, Inc. (NASDAQ: PSTV) shares rose 31.2% to $0.6931 in pre-market trading as...
By Benzinga - 24 weeks ago

Clene to Host VISIONARY-MS Results Call and Webcast on August 15
Clene to Host VISIONARY-MS Results Call and Webcast on August 15

SALT LAKE CITY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with...
By GlobeNewswire Inc. - 24 weeks ago

Will Clene Inc. (CLNN) Report Negative Q2 Earnings? What You Should Know
Will Clene Inc. (CLNN) Report Negative Q2 Earnings? What You Should Know

Clene Inc. (CLNN) doesn't possess the right combination of the two key ingredients for a...
By Zacks Investment Research - 25 weeks ago